三阴性乳腺癌的分子生物学及治疗进展

doi:10.3760/cma.j.issn.1673422X.2016.07.011

摘要/Abstract

摘要： 三阴性乳腺癌（TNBC）难以获益于内分泌治疗或曲妥珠单抗靶向药物治疗，乳腺癌易感基因1、p53基因、血管内皮生长因子、微小RNA等的生物过表达提示其易转移复发和较差的预后。探索TNBC的分子亚型、制定针对亚分类的治疗方案、寻找相应单克隆抗体的靶点是今后的研究方向。

关键词: 乳腺肿瘤, 分子生物学, 基因, 治疗

Abstract: Triple negative breast cancer (TNBC) is difficult to benefit from endocrine therapy or trastuzumab targeted drug therapy. Biological overexpression of breast cancer susceptibility gene 1, p53 gene, vascular endothelial growth factor and microRNA suggests that TNBC is easy to metastasis and recurrence and has a poor prognosis. Exploring the molecular subtypes of TNBC, setting out the treatment plan for subtypes and finding the corresponding monoclonal antibody targets are the research direction of TNBC in the future.

Key words: Breast neoplasms, Molecular biology, Genes, Therapy

刘俊杰, 钱军. 三阴性乳腺癌的分子生物学及治疗进展[J]. 国际肿瘤学杂志, 2016, 43(7): 526-528.

LIU Jun-Jie, QIAN Jun. Progress of molecular biology and treatment for triple negative breast cancer[J]. Journal of International Oncology, 2016, 43(7): 526-528.

参考文献

［1］ Abkevich V, Timms KM, Hennessy BT, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer［J］. Br J Cancer， 2012, 107(10): 17761782. DOI: 10.1038/bjc.2012.451. ［2］ Liedtke C, Hess KR, Karn T, et al. The prognostic impact of age in patients with triplenegative breast cancer［J］. Breast Cancer Res Treat, 2013, 138(2): 591599. DOI: 10.1007/s105490132461x. ［3］ Medimegh I, Omrane I, Privat M, et al. MicroRNAs expression in triple negative vs non triple negative breast cancer in Tunisia: interaction with clinical outcome［J］. PLoS One, 2014, 9(11): e111877. DOI: 10.1371/journal.pone.0111877. ［4］ Lehmann BD, Bauer JA, Chen X, et al. Identification of human triplenegative breast cancer subtypes and preclinical models for selection of targeted therapies［J］. J Clin Invest, 2011, 121(7): 27502767. DOI: 10.1172/JCI45014. ［5］ Bousquet G, Feugeas JP, Ferreira I, et al. Individual xenograft as a personalized therapeutic resort for women with metastatic triplenegative breast carcinoma［J］. Breast Cancer Res, 2014, 16(1): 401. DOI: 10.1186/bcr3615. ［6］ Narod SA, Salmena L. BRCA1 and BRCA2 mutations and breast cancer［J］. Discov Med, 2011, 12(66): 445453. ［7］ Fasano J, Muggia F. Breast cancer arising in a BRCAmutated background: therapeutic implications from an animal model and drug development［J］. Ann Oncol, 2009, 20(4): 609614. DOI: 10.1093/annonc/mdn669. ［8］ Kojima Y, Tsunoda H, Honda S, et al. Radiographic features for triple negative ductal carcinoma in situ of the breast［J］. Breast Cancer, 2011, 18(3): 213220. DOI: 10.1007/s122820110261x. ［9］陈曲, 哈敏文, 包翠芬. BRCA1在三阴性乳腺癌中的表达及意义［J］. 数理医药学杂志, 2012, 25(5): 513515. DOI: 10.3969/j.issn.10044337.2012.05.004. ［10］ Walerych D, Napoli M, Collavin L, et al. The rebel angel: muant p53 as the driving oncogene in breast cancer［J］. Carcinogenesis, 2012, 33(11): 20072017. DOI: 10.1093/carcin/bgs232. ［11］ Thompson AM, Lane DP. P53 transcriptional pathways in breast cancer: the good, the bad and the complex［J］. J Pathol, 2010, 220(4): 401403. DOI: 10.1002/path.2674. ［12］ Bieging KT, Attardi LD. Deconstructing p53 transcriptional networks in tumor suppression［J］. Trends Cell Biol, 2012, 22(2): 97106. DOI: 10.1016/j.tcb.2011.10.006. ［13］栗艳松. VEGF和P53在三阴性乳腺癌中的表达及临床意义［J］. 河北医药, 2014, 36(19): 29032905. DOI: 10.3969/j.issn.10027386.2014.19.007. ［14］张勤, 刘红. P53在三阴性乳腺癌中的表达及临床意义［J］. 中国肿瘤临床, 2011, 38(4): 214217. DOI: 10.3969/j.issn.10008179.2011.04.010. ［15］ Sharma G, Mirza S, Parshad R, et al. Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGFA and MTA1 expression［J］. Tumour Biol, 2011, 32(1): 2332. DOI: 10.1007/s1327701000878. ［16］杨晨, 虞佩, 李济宇, 等. 微RNA375在三阴性乳腺癌中的表达及生物学效应［J］. 上海交通大学学报: 医学版, 2014, 34(11): 15861589. DOI:11.3969/j.issn.16748115.2014.11.005. ［17］ Cascione L, Gasparini P, Lovat F, et al. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer［J］. PLoS One, 2013, 8(2): e55910. DOI: 10.1371/journal.pone.0055910. ［18］ MartinezRamos D, EscrigSos J, TorrellaRamos A, et al. Is conservative surgery a good option for patients with "triple negative" breast cancer?［J］. Breast, 2012, 21(3): 401405. DOI: 10.1016/j.breast.2012.04.005. ［19］ Steward LT, Gao F, Taylor MA, et al. Impact of radiation therapy on survival in patients with triple negative breast cancer［J］. Oncol Lett, 2014, 7(2): 548552. DOI: 10.3892/ol.2013.1700. ［20］ Caudle AS, Yu TK, Tucker SL, et al. Localregional control according to surrogate markers of breast cancer subtypes and response toneoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy［J］. Breast Cancer Res, 2012, 14(3): R83. DOI: 10.1186/bcr3198. ［21］ Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant onceperweek paclitaxel followed by dosedense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triplenegative breast cancer: CALGB 40603 (Alliance)［J］. J Clin Oncol, 2015, 33(1): 1321. DOI: 10.1200/JCO.2014.57.0572. ［22］ O′Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triplenegative breast cancer［J］. N Engl J Med, 2011, 364(3): 205214. DOI: 10.1056/NEJMoa1011418. ［23］ Chen XS, Yuan Y, Garfield DH, et al. Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a metaanalysis［J］. PLoS One, 2014, 9(9): e108405. DOI: 10.1371/journal.pone.0108405.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[4]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[5]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[6]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[7]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[8]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[9]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[10]	王子豪, 王宇, 杨鑫, 何艺, 莫兴奎, 袁涛. 铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 239-244.
[11]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[12]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[13]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[14]	岳红云, 张百红. 肿瘤的分化治疗[J]. 国际肿瘤学杂志, 2024, 51(2): 109-113.
[15]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.